Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Precision medicine in inflammatory bowel disease: concept, progress and challenges.

Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R.

F1000Res. 2020 Jan 28;9. pii: F1000 Faculty Rev-54. doi: 10.12688/f1000research.20928.1. eCollection 2020. Review.

2.

Personalising medicine in inflammatory bowel disease-current and future perspectives.

Ashton JJ, Mossotto E, Ennis S, Beattie RM.

Transl Pediatr. 2019 Jan;8(1):56-69. doi: 10.21037/tp.2018.12.03. Review.

3.

The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.

Carroll MW, Kuenzig ME, Mack DR, Otley AR, Griffiths AM, Kaplan GG, Bernstein CN, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Benchimol EI.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.

4.

The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.

Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.

5.

Inflammatory bowel disease. Part I: Nature and pathogenesis.

Kirsner JB.

Dis Mon. 1991 Oct;37(10):605-66. Review.

PMID:
1893828
6.

Challenges in IBD Research: Precision Medicine.

Denson LA, Curran M, McGovern DPB, Koltun WA, Duerr RH, Kim SC, Sartor RB, Sylvester FA, Abraham C, de Zoeten EF, Siegel CA, Burns RM, Dobes AM, Shtraizent N, Honig G, Heller CA, Hurtado-Lorenzo A, Cho JH.

Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S31-S39. doi: 10.1093/ibd/izz078.

PMID:
31095701
7.

Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.

Kirsner JB.

Dis Mon. 1991 Nov;37(11):669-746. Review.

PMID:
1935537
8.

The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.

Bernstein CN, Benchimol EI, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Kaplan GG.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S73-S80. doi: 10.1093/jcag/gwy053. Epub 2018 Nov 2.

9.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
10.

How does genotype influence disease phenotype in inflammatory bowel disease?

Ananthakrishnan AN, Xavier RJ.

Inflamm Bowel Dis. 2013 Aug;19(9):2021-30. doi: 10.1097/MIB.0b013e318281f5c5. Review.

11.

Exercise in patients with inflammatory bowel diseases: current perspectives.

Engels M, Cross RK, Long MD.

Clin Exp Gastroenterol. 2017 Dec 22;11:1-11. doi: 10.2147/CEG.S120816. eCollection 2018. Review.

12.

Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy.

Fiocchi C.

Minerva Gastroenterol Dietol. 2002 Sep;48(3):215-26.

PMID:
16491045
13.

Inflammatory bowel disease pathogenesis: where are we?

Fiocchi C.

J Gastroenterol Hepatol. 2015 Mar;30 Suppl 1:12-8. doi: 10.1111/jgh.12751. Review.

PMID:
25827798
14.

Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.

Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.

Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.

PMID:
27149138
15.

Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?

Lindholm CR, Siegel CA.

Curr Pharm Des. 2019;25(1):64-68. doi: 10.2174/1381612825666190312113935. Review.

PMID:
30864506
16.

Crohn's and colitis in children and adolescents.

Day AS, Ledder O, Leach ST, Lemberg DA.

World J Gastroenterol. 2012 Nov 7;18(41):5862-9. doi: 10.3748/wjg.v18.i41.5862. Review.

17.

Familial occurrence and inheritance studies in inflammatory bowel disease.

Binder V, Orholm M.

Neth J Med. 1996 Feb;48(2):53-6. Review.

PMID:
8819799
18.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
19.

The exposome in inflammatory bowel disease.

Ananthakrishnan AN.

Trop Gastroenterol. 2014 Jul-Sep;35(3):135-40. Review.

PMID:
26012316
20.

Clinical Genomics in Inflammatory Bowel Disease.

Uhlig HH, Muise AM.

Trends Genet. 2017 Sep;33(9):629-641. doi: 10.1016/j.tig.2017.06.008. Epub 2017 Jul 26. Review.

Supplemental Content

Support Center